# A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.

> **NCT03469011** · PHASE1 · TERMINATED · sponsor: **AHS Cancer Control Alberta** · enrollment: 14 (actual)

## Conditions studied

- Papillary Thyroid Cancer

## Interventions

- **DRUG:** Imatinib Oral Tablet

## Key facts

- **NCT ID:** NCT03469011
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-18
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Lack of Accrual
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03469011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03469011, "A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03469011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*